For the year ending 2025-12-31, PTCT had $203,018K increase in cash & cash equivalents over the period. $702,336K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Total revenues | 1,730,655 |
| Cost of product, collaboration and license sales | 28,427 |
| Program spend | 201,706 |
| Employee costs | 283,583 |
| Manufacturing costs | 67,323 |
| Administrative costs | 73,805 |
| Occupancy costs | 29,561 |
| Total other segment items | 363,606 |
| Net income (loss) attributable to common stockholders | 682,644 |
| Depreciation and amortization | 38,815 |
| Non-cash operating lease expense | 7,467 |
| Non-cash royalty revenue related to sale of future royalties | 228,568 |
| Non-cash interest expense on liability related to sale of future royalties | 215,158 |
| Change in valuation of contingent consideration | -800 |
| Tangible asset impairment | 1,018 |
| Loss on sale of fixed assets | -130 |
| Gain on lease modification | 10,775 |
| Unrealized (gain) loss on clearpoint equity investments | 5,734 |
| Realized loss on sale of clearpoint equity investment | -7,081 |
| Unrealized gain on marketable securities - equity investments | 3,960 |
| Disposal of asset | -163 |
| Deferred income taxes | -3 |
| Amortization of discounts on investments, net | 18,022 |
| Amortization of debt issuance costs | 1,219 |
| Share-based compensation expense | 74,547 |
| Unrealized foreign currency transaction losses (gains), net | -3,380 |
| Inventory, net | 53,896 |
| Prepaid expenses and other current assets | 36,818 |
| Trade and royalty receivables, net | 10,151 |
| Deposits and other assets | -2,638 |
| Accounts payable and accrued expenses | 71,741 |
| Other liabilities | -17,396 |
| Deferred revenue | -3,998 |
| Payments on contingent consideration | -4,684 |
| Net cash provided by (used in) operating activities | 711,196 |
| Purchases of fixed assets | 8,860 |
| Proceeds from sale of fixed assets | 70 |
| Purchases of marketable securities- available for sale | 1,363,530 |
| Purchases of marketable securities- equity investments | 53,628 |
| Sale of marketable securities- available for sale | 783,896 |
| Sale of marketable securities- equity investments | 58,808 |
| Sale of clearpoint equity investments | 12,412 |
| Acquisition of product rights and licenses | 291,152 |
| Net cash (used in) provided by investing activities | -861,984 |
| Proceeds from exercise of options | 93,102 |
| Proceeds from employee stock purchase plan | 5,944 |
| Cash consideration received from a&r royalty purchase agreement | 240,000 |
| Payments on contingent consideration obligation | 6,341 |
| Payment of finance lease principal | 1,611 |
| Net cash provided by financing activities | 331,094 |
| Effect of exchange rate changes on cash | 22,712 |
| Net increase in cash and cash equivalents | 203,018 |
PTC THERAPEUTICS, INC. (PTCT)
PTC THERAPEUTICS, INC. (PTCT)